<div id="readability-page-1"><div><p>3SBio (SEHK:1530) has just posted its FY 2025 first half results, with revenue of ¥4.4b and basic EPS of ¥0.57, while trailing twelve month EPS stands at ¥3.51 on revenue of ¥17.7b. This points to a period where profitability has been heavily supported by strong net income levels. Looking back, the company has seen half year revenue move from ¥4.39b and EPS of ¥0.45 in 2024 H1 to ¥4.36b and EPS of ¥0.41 in 2024 H2, before landing at the current ¥4.36b and ¥0.57 in 2025 H1. This sets up a results season where investors are likely to focus on how far current margins can be maintained.</p> <p>See our full analysis for 3SBio.</p><p>With the headline numbers on the table, the next step is to see how this earnings print lines up with the prevailing stories around 3SBio and where the data challenges those views.</p> <p>Curious how numbers become stories that shape markets? Explore Community Narratives</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3a5750e6-3e5c-4eac-b38b-05dd7044b109/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTAzLTMx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3a5750e6-3e5c-4eac-b38b-05dd7044b109/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTAzLTMx"/><figcaption>SEHK:1530 Earnings &amp; Revenue History as at Mar 2026</figcaption></figure> <h2>Net Margin Near 48% On Trailing Basis</h2> <ul> <li>On the trailing twelve month numbers, 3SBio reports net income of ¥8.5b on ¥17.7b of revenue, which translates to a 47.9% net margin compared with 23% in the prior year period.</li> <li>What stands out for a more bullish angle is that this very large earnings jump of 305.8% over the past year sits alongside that 47.9% margin, which heavily supports the idea that recent profitability is not just about top line size but also about how much of each yuan is being kept as profit.     <ul> <li>Over the last twelve months, net income reached ¥8.5b on ¥17.7b of revenue, while five year annualized earnings growth is reported at 32.3% per year.</li> <li>This combination of strong reported margin and multi year earnings growth gives bullish investors concrete figures to point to when they argue that the business model has been earning solid returns over this period.</li> </ul> </li> </ul> <p>Some investors want to see how this profit profile stacks up against other views on the company. The community narrative brings those perspectives together in one place Curious how numbers become stories that shape markets? Explore Community Narratives.</p> <h2>Valuation Signals Look Compressed</h2> <ul> <li>The shares trade on a P/E of 5.9x compared with 38.1x for the Asian Biotechs industry and 65.3x for peers. The current price of HK$22.64 is also well below the cited DCF fair value of HK$54.87.</li> <li>Critics highlight that even with this low P/E and the gap to the DCF fair value, the same dataset flags that revenue is forecast to decline by 21.2% per year and earnings by 53.4% per year over the next three years, so the compressed multiple may be reflecting those projections rather than ignoring them.     <ul> <li>The forecasted earnings contraction contrasts sharply with the trailing 305.8% earnings growth, which means bearish investors can argue that the recent twelve month strength is not what the forward numbers are built on.</li> <li>Because the stock trades around 58.7% below the DCF fair value estimate while carrying those decline forecasts, both bulls and bears can find support in the same set of figures when they debate whether the current valuation is attractive.</li> </ul> </li> </ul> <h2>Half Year Profitability Outpaces Revenue</h2> <ul> <li>In 2025 H1, revenue of ¥4,355.5m sits slightly below the ¥4,718.5m reported in 2024 H2, yet net income excluding extra items is ¥1,358.2m compared with ¥1,000.4m in 2024 H2 and ¥1,089.9m in 2024 H1.</li> <li>What is surprising for a more bearish reading is that the main flagged risk is the forecast decline in earnings and revenue, yet within the last three half year periods net income excluding extra items has moved from ¥1,089.9m to ¥1,000.4m to ¥1,358.2m while basic EPS has moved from ¥0.45 to ¥0.41 to ¥0.57. This gives bears a clear tension between the historical profit pattern and the forward projections they are relying on.     <ul> <li>Over the same halves, revenue has stayed in a fairly tight band around ¥4.4b to ¥4.7b, while the trailing period as a whole sums to ¥17.7b, showing that the stronger trailing margin is being measured on a revenue base that has not surged.</li> <li>This mix of steady recent revenue, rising trailing margin to 47.9% and very large reported earnings growth against forecasts of multi year decline is exactly the kind of data gap cautious investors point to when they argue that the recent run rate may not persist.</li> </ul> </li> </ul> <h2>Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on 3SBio's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.</p> <p>Seeing both strong margins and cautious forecasts in the numbers, it makes sense to check the details yourself and pressure test the story from every angle. To balance the optimism and concerns already flagged, take a closer look at the company's 3 key rewards and 1 important warning sign: 3 key rewards and 1 important warning sign.</p> <h2>See What Else Is Out There</h2> <p>For all the strong trailing margins, the key concern is that revenue and earnings are forecast to decline sharply despite recent profit strength.</p> <p>If those projected declines make you uneasy, it is worth widening your search to companies flagged as attractively priced with solid fundamentals through the 254 high quality undervalued stocks.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if 3SBio might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

01530

<p>3SBio (SEHK:1530) reported FY 2025 H1 results with revenue of ¥4.4b and EPS of ¥0.57, maintaining a strong net margin of 47.9%. Despite a significant earnings growth of 305.8% over the past year, forecasts predict a decline in revenue and earnings over the next three years. The stock trades at a low P/E of 5.9x, well below the industry average, raising questions about future profitability. Investors are divided, with bullish views on current margins and bearish concerns over projected declines.</p>

3SBio (SEHK:1530) Trailing 48% Net Margin Challenges Bearish Earnings Decline Narrative